Pfizer Inc

PFE vs. ABBV Switch to Abbvie. The whole pharma business has trouble at a structural level. They spend millions developing drugs, then watch the clock wind down till the generics can compete. Abbvie gives you an exciting bio-pharma alternative. Problem in the past was its one-drug focus, but the Allergan purchase diluted this risk. About 10x earnings, not expensive, great cash flow, good dividend.

Went over the patent cliff and is in the process of redeveloping its pipeline. Attractive yield. Owns JNJ instead, because she likes its diversity, and its product pipeline is strong. PFE has a strong balance sheet, but JNJ's is stronger. JNJ's medical device side is recovering nicely, plus they were able to give guidance at a time when many companies can't.

Main attractions are its cash flow and dividend. Being held back by low earnings growth, low single digits. Instead, look at Abbvie, Merck, or other names with growth but similar valuations.

ABT-N vs. PFE-N. Abbot Labs has a Great franchise. Very well loved by the investment community. You are really not getting any opportunity to invest at a cheaper valuation. PFE-N is somewhat of a drug ETF. They have a big portfolio. You are bidding on their strategy of buying and selling drug lines. This one will be well positioned. The entry price is not the greatest but you could buy it and you would be fine.

It is still very cheap in his opinion. It is cheaper than the market multiple. It is growing revenue, earnings and dividends as well as buying back stock. About a 4% dividend yield. A great management team. They merged their consumer business with GSK-N. There should be a boost to the share price when this gets IPOed in two to three years. In the near term there is their generic drug business that is merging with MYL-Q. They will then be an innovation-focused and higher growth R&D kind of Pfizer. (Analysts’ price target is $41.80)